Recombinant Klebsiella pneumoniae subsp. pneumoniae Elongation factor Tu (tufA)

What is Elongation Factor Tu (EF-Tu) and what is its functional significance in K. pneumoniae?

Elongation Factor Tu (EF-Tu) is a highly conserved GTP-binding protein encoded by the tufA gene that plays an essential role in bacterial protein synthesis. In K. pneumoniae, as in other bacteria, EF-Tu functions in the elongation phase of translation by delivering aminoacyl-tRNAs to the ribosome. Beyond this canonical role, immunoproteomic analysis has identified EF-Tu as a potential pathogenicity factor in K. pneumoniae infections, particularly in bacteremia associated with leukopenia .

The protein typically comprises approximately 5-10% of total bacterial protein, reflecting its critical importance in bacterial physiology. Structurally, EF-Tu consists of three domains: Domain 1 (the G domain) that binds GTP/GDP, and Domains 2 and 3 involved in aminoacyl-tRNA binding. This structural organization enables EF-Tu to undergo conformational changes during the translation cycle, transitioning between GTP-bound (active) and GDP-bound (inactive) states.

Recent research has revealed that EF-Tu may serve additional "moonlighting" functions beyond translation, including roles in pathogenicity, stress response, and potentially in antimicrobial resistance mechanisms. The validation study using western blotting demonstrated that K. pneumoniae isolates associated with leukopenia exhibited significantly higher EF-Tu expression compared to those associated with leukocytosis, confirming its potential role as a virulence factor .

What molecular characteristics distinguish K. pneumoniae EF-Tu?

K. pneumoniae EF-Tu is a GTP-binding protein with a molecular weight of approximately 43 kDa and typically has an isoelectric point between 5 and 6, consistent with its detection in the 4 to 7 pI range in immunoproteomic studies . The protein exhibits high sequence conservation across bacterial species, particularly in functional regions such as the GTP-binding domain.

Key molecular characteristics include:

Studies have shown that K. pneumoniae EF-Tu can be differentially expressed under various growth conditions and during infection, suggesting regulation mechanisms that may contribute to its pathogenic role . The protein's abundance and essential nature make it a significant potential target for both diagnostic and therapeutic development.

What methods are commonly used to clone and express recombinant K. pneumoniae tufA?

Cloning and expressing recombinant K. pneumoniae tufA involves several methodological steps, each requiring optimization for successful production of functional protein:

• Gene Amplification and Cloning Strategy

  • PCR amplification of the tufA gene (~1.2 kb) from K. pneumoniae genomic DNA using high-fidelity polymerase

  • Design of primers incorporating compatible restriction sites for directional cloning

  • Insertion into appropriate expression vectors (pET series vectors are commonly used)

  • Addition of affinity tags (His6, GST, or MBP) to facilitate purification

• Expression System Selection

  • E. coli BL21(DE3) or derivatives are typically preferred due to high protein yield and ease of manipulation

  • Rosetta strains can be used if codon bias is a concern

  • Arctic Express strains can improve folding at lower temperatures

• Expression Optimization Protocol

  • Temperature: Lower temperatures (16-25°C) often enhance solubility

  • IPTG concentration: 0.1-0.5 mM typically provides optimal induction

  • Duration: 4-16 hours depending on temperature

  • Media selection: Rich media (LB, TB) or minimal media depending on downstream applications

• Purification Strategy

  • Immobilized metal affinity chromatography (IMAC) for His-tagged proteins

  • Size exclusion chromatography to remove aggregates and ensure homogeneity

  • Ion exchange chromatography for further purification if necessary

  • Buffer optimization to maintain protein stability

For functional studies, it is particularly important to verify that the recombinant protein retains GTP-binding and hydrolysis capabilities, as these are essential for EF-Tu's biological activity. This can be assessed through GTPase assays and structural analyses.

How does EF-Tu expression correlate with pathogenicity in K. pneumoniae infections?

Immunoproteomic studies have revealed a significant correlation between EF-Tu expression and K. pneumoniae pathogenicity, particularly in infections leading to leukopenia. Western blotting validation confirmed that K. pneumoniae isolates from patients with leukopenia exhibited higher EF-Tu expression compared to isolates from patients with leukocytosis . This finding suggests that EF-Tu may play a key role in the pathogenicity mechanisms that suppress white blood cell production or function during infection.

Several mechanisms may underlie EF-Tu's contribution to K. pneumoniae pathogenicity:

• Immunomodulation: EF-Tu may interact with host immune components, potentially suppressing leukocyte function or production

• Host Cell Adhesion: Surface-exposed EF-Tu could mediate attachment to host cells

• Stress Response Coordination: EF-Tu might help coordinate bacterial adaptation to host defense mechanisms

• Biofilm Formation: Potential involvement in biofilm development, which is associated with antimicrobial resistance in K. pneumoniae isolates

The differential expression of EF-Tu between strains causing different clinical manifestations provides strong evidence for its role as a pathogenicity factor. This is particularly significant when considered alongside the identification of other pathogenicity factors in the same study, including S-adenosylmethionine synthetase, pyruvate dehydrogenase, glutathione synthetase, UDP-galactose-4-epimerase, and acetate kinase A .

The correlation between EF-Tu expression and leukopenia suggests that targeting this protein could represent a novel therapeutic strategy for managing severe K. pneumoniae infections, particularly in the context of increasing antimicrobial resistance.

What are the challenges in purifying active recombinant K. pneumoniae EF-Tu protein?

Purifying active recombinant K. pneumoniae EF-Tu presents several technical challenges that researchers must address to obtain functional protein suitable for structural and biochemical studies:

• Maintaining Conformational Integrity

  • EF-Tu undergoes significant conformational changes between GTP and GDP-bound states

  • Purification conditions must preserve this conformational flexibility

  • Buffer composition (particularly Mg²⁺ concentration) critically affects nucleotide binding

• Solubility and Folding Challenges

  • Expression at standard conditions often leads to inclusion body formation

  • Optimization strategies include:

    • Reduced induction temperature (16-20°C)

    • Lower IPTG concentrations (0.1-0.2 mM)

    • Co-expression with chaperones

    • Fusion with solubility-enhancing tags (MBP, SUMO)

• Preserving GTPase Activity

  • GTPase activity is essential for functional studies

  • Activity can be compromised during purification steps

  • Rapid purification protocols and addition of stabilizing agents (glycerol, reducing agents) help preserve activity

• Protein Stability Considerations

  • EF-Tu may aggregate during concentration steps

  • Long-term storage often results in activity loss

  • Optimization of storage conditions (buffer components, temperature) is critical

• Post-translational Modifications

  • K. pneumoniae may modify EF-Tu in ways not replicated in heterologous systems

  • These modifications may be important for pathogenicity functions

  • Native purification from K. pneumoniae may be necessary for certain studies

To address these challenges, researchers typically employ a systematic approach to optimization, testing multiple expression systems, purification strategies, and buffer conditions. Functional validation through GTPase assays, thermal shift assays, and circular dichroism is essential to confirm that the purified protein maintains its native properties.

How can recombinant tufA be used to study the role of EF-Tu in antimicrobial resistance?

Recombinant tufA provides a powerful tool for investigating EF-Tu's potential contributions to antimicrobial resistance in K. pneumoniae through several experimental approaches:

• Structure-Function Studies

  • Crystallization of recombinant EF-Tu with antibiotics that target the translational machinery

  • Site-directed mutagenesis to identify residues involved in antibiotic interactions

  • Comparison of EF-Tu structures from resistant versus susceptible strains

• Expression Level Analysis

  • Quantitative comparison of tufA expression in resistant versus susceptible isolates

  • Correlation of expression levels with minimum inhibitory concentrations (MICs)

  • Evaluation of expression changes upon antibiotic exposure

• Interaction Studies

  • Pull-down assays using recombinant EF-Tu to identify interactions with other resistance-associated proteins

  • Surface plasmon resonance to measure binding kinetics with antibiotics and resistance factors

  • Yeast two-hybrid or bacterial two-hybrid screens for protein-protein interactions

• Biofilm Formation Assessment

  • Investigation of EF-Tu's role in biofilm development, which is associated with antibiotic resistance

  • Complementation studies with recombinant EF-Tu in tufA mutants

  • Antibody-mediated inhibition of EF-Tu function in biofilm formation assays

• In vivo Resistance Models

  • Expression of wild-type versus mutant tufA in susceptible strains to assess contribution to resistance

  • Zebrafish infection models to evaluate the efficacy of EF-Tu-targeting strategies in vivo

  • Competitive growth assays in the presence of antibiotics

This research is particularly relevant given the identified association between biofilm formation in K. pneumoniae isolates and antibiotic resistance patterns, with multiple drug-resistant (MDR) isolates showing stronger biofilm formation capacity . Understanding EF-Tu's potential role in these resistance mechanisms could lead to novel therapeutic strategies for combating increasingly problematic K. pneumoniae infections.

What techniques are effective for studying EF-Tu interactions with host cells during infection?

Studying EF-Tu interactions with host cells during K. pneumoniae infection requires sophisticated methodological approaches that span from molecular to cellular and in vivo systems:

• Co-immunoprecipitation and Pull-down Assays

  • Use recombinant EF-Tu as bait to capture interacting host proteins

  • Employ antibodies against EF-Tu to precipitate protein complexes from infected cells

  • Identify binding partners through mass spectrometry

  Protocol Enhancement: Crosslinking prior to lysis increases the chance of capturing transient interactions

• Advanced Microscopy Techniques

  • Immunofluorescence microscopy to visualize EF-Tu localization during infection

  • Fluorescence resonance energy transfer (FRET) to detect direct protein-protein interactions

  • Super-resolution microscopy (STORM, PALM) for nanoscale visualization of interaction sites

  Quantification Method: Calculate Manders' overlap coefficient to measure co-localization

• Surface Plasmon Resonance

  • Measure binding kinetics between purified EF-Tu and candidate host receptors

  • Determine affinity constants (KD) for various interactions

  • Evaluate how mutations or post-translational modifications affect binding

• Cell-based Functional Assays

  • Competitive inhibition with recombinant EF-Tu or antibodies

  • Transfection of host cells with constructs expressing potential interacting partners

  • Measurement of downstream signaling events (e.g., cytokine production, NF-κB activation)

  Readouts: Cytokine ELISAs, reporter assays, phosphorylation status of signaling proteins

• In vivo Models

  • Zebrafish larvae model for visualizing host-pathogen interactions

  • Murine infection models comparing wild-type and EF-Tu-modified K. pneumoniae

  • Histopathological analysis of infected tissues with immunostaining for EF-Tu

• Transcriptomic and Proteomic Profiling

  • RNA-seq of host cells exposed to recombinant EF-Tu

  • Immunoproteomics to identify differential expression patterns, as used in the identification of EF-Tu as a pathogenicity factor

  • Phosphoproteomics to map signaling cascades activated upon EF-Tu exposure

These methodologies, particularly when used in combination, can provide comprehensive insights into how EF-Tu contributes to K. pneumoniae pathogenicity, especially in the context of leukopenia development during infection as suggested by the immunoproteomic study .

How can tufA be used as a molecular marker for K. pneumoniae identification and typing?

The tufA gene offers several advantages as a molecular marker for K. pneumoniae identification and typing in both research and diagnostic settings:

• PCR-Based Detection Methods

  • Species-specific PCR targeting conserved regions of tufA

  • Real-time quantitative PCR for rapid and sensitive detection

  • High-resolution melt (HRM) analysis for strain differentiation

  Sensitivity Enhancement: Nested PCR approaches can detect as few as 10 CFU in clinical samples

• Sequence Analysis Approaches

  • Single nucleotide polymorphism (SNP) analysis within tufA

  • Multi-locus sequence typing (MLST) incorporating tufA

  • Whole gene sequencing for high-resolution strain typing

  Workflow: DNA extraction → PCR amplification → Sequencing → Alignment → Phylogenetic analysis

• Phylogenetic Applications

  • Construction of phylogenetic trees to establish evolutionary relationships

  • Identification of clonal groups in outbreak investigations

  • Determination of geographical distribution patterns

  Rationale: The tufA gene has proven to be an effective marker with monophyletic association as the main criteria for species identification

• Restriction Fragment Length Polymorphism (RFLP)

  • Digestion of tufA amplicons with restriction enzymes

  • Gel electrophoresis pattern analysis for strain differentiation

  • Rapid and economical approach for preliminary typing

  Statistical Analysis: Calculate Simpson's Index of Diversity to evaluate discriminatory power

• Expression Level Analysis

  • Quantitative PCR to measure tufA expression levels

  • Correlation with virulence phenotypes

  • Potential biomarker for strains likely to cause leukopenia

The following table summarizes the comparative advantages of different tufA-based typing methods:

The selection of the appropriate tufA-based typing method depends on the specific research or diagnostic question, available resources, and required resolution level.

What are optimal expression systems for producing functional recombinant K. pneumoniae EF-Tu?

The production of functional recombinant K. pneumoniae EF-Tu requires careful selection and optimization of expression systems. The following approaches have proven effective for obtaining high yields of active protein:

• Bacterial Expression Systems

  E. coli BL21(DE3) and Derivatives

  • Standard system for high-level expression

  • Optimization parameters:

    • Induction at OD600 0.6-0.8

    • IPTG concentration: 0.1-0.5 mM

    • Temperature: 16-25°C for 16-20 hours

    • Media: TB or auto-induction media for higher yields

  Specialized Strains

  • Rosetta strains for rare codon optimization

  • Arctic Express for improved folding at low temperatures

  • SHuffle strains for disulfide bond formation if needed

  Advantages: High yield, cost-effective, simple scale-up

• Expression Vector Selection

  pET Series Vectors

  • pET28a(+) for N or C-terminal His-tag

  • pET32a(+) for thioredoxin fusion to enhance solubility

  • pET-SUMO for SUMO fusion with cleavable tag

  Alternative Vectors

  • pMAL-c5X for MBP fusion (enhances solubility)

  • pGEX for GST fusion (facilitates purification)

  • pCold for cold-shock induced expression

  Tag Considerations: N-terminal tags less likely to interfere with GTP binding compared to C-terminal tags

• Cell-free Expression Systems

  E. coli Extract-based Systems

  • Rapid production (4-6 hours)

  • Direct incorporation of labeled amino acids

  • Avoids toxicity issues

  Protocol Parameters:

  • Template concentration: 10-15 μg/mL

  • Reaction temperature: 30°C

  • Reaction time: 4-6 hours

  Applications: NMR studies, rapid screening of constructs

• Eukaryotic Expression Systems

  Insect Cell Expression

  • Baculovirus-mediated expression in Sf9 or Hi5 cells

  • More likely to incorporate post-translational modifications

  • Slower (5-7 days) but may yield more properly folded protein

  Yeast Expression

  • Pichia pastoris for secreted expression

  • Saccharomyces cerevisiae for intracellular expression

  Advantages: Better folding machinery, suitable for complex proteins

The choice of expression system should be guided by the intended application of the recombinant protein. For structural studies, higher purity and homogeneity are critical, while functional assays may tolerate lower purity but require preserved activity.

How can structural studies of recombinant EF-Tu inform therapeutic development against K. pneumoniae?

Structural studies of recombinant K. pneumoniae EF-Tu can significantly accelerate therapeutic development through several approaches:

• Target-Based Drug Design

  • High-resolution crystal or cryo-EM structures reveal druggable pockets

  • Computational screening of virtual compound libraries against these structures

  • Structure-activity relationship (SAR) studies to optimize lead compounds

  Strategic Approach: Focus on regions unique to bacterial EF-Tu compared to human elongation factors

• Allosteric Inhibitor Development

  • Identification of conformational transitions specific to EF-Tu function

  • Design of molecules that stabilize inactive conformations

  • Targeting of interfaces between EF-Tu and other components of the translation machinery

  Advantage: Potentially lower resistance development compared to active site inhibitors

• Fragment-Based Drug Discovery

  • Screening of fragment libraries against EF-Tu structures

  • X-ray crystallography and NMR to detect binding events

  • Fragment growing, linking, or merging to develop high-affinity compounds

  Experimental Workflow: Fragment library → Thermal shift assay → X-ray/NMR validation → Fragment optimization

• Peptide Inhibitor Development

  • Design of peptides that mimic natural binding partners

  • Peptidomimetics that disrupt essential protein-protein interactions

  • Stapled peptides for enhanced stability and cell penetration

  Target Interactions: EF-Tu:EF-Ts, EF-Tu:aminoacyl-tRNA, or EF-Tu:ribosome interfaces

• Structure-Guided Vaccine Development

  • Identification of surface-exposed, conformationally stable epitopes

  • Design of recombinant immunogens presenting these epitopes

  • Structural validation of antibody binding to target epitopes

  Rationale: EF-Tu's identification as a pathogenicity factor makes it a logical vaccine target

This approach is particularly valuable given the increasing prevalence of multiple drug-resistant K. pneumoniae causing nosocomial infections . The identification of EF-Tu as a pathogenicity factor specifically associated with leukopenia suggests that targeting this protein could potentially reduce virulence without imposing strong selective pressure for resistance development.

What role does EF-Tu play in K. pneumoniae biofilm formation and antimicrobial resistance?

While direct evidence for EF-Tu's role in K. pneumoniae biofilm formation is still emerging, several lines of investigation suggest important contributions to both biofilm development and antimicrobial resistance:

• Biofilm Matrix Contributions

  • EF-Tu may be released into the extracellular environment during biofilm formation

  • Potential role as an adhesin facilitating bacterial attachment

  • Possible contribution to extracellular matrix stability

  Relevant Finding: K. pneumoniae isolates that form strong biofilms (optical density: 0.76-0.92) often exhibit multiple antibiotic resistance

• Stress Response Coordination

  • EF-Tu participates in bacterial stress responses beyond its translation function

  • May help orchestrate physiological adaptations during biofilm formation

  • Could contribute to the stress-resistant phenotype of biofilm cells

  Experimental Approach: Comparative proteomics of planktonic versus biofilm cells to quantify EF-Tu levels

• Translational Regulation

  • Selective translation of specific mRNAs during biofilm development

  • Potential roles in adjusting protein synthesis during transitions between planktonic and biofilm states

  • Possible involvement in producing biofilm-specific proteins

  Research Direction: Ribosome profiling in biofilm versus planktonic cells

• Antibiotic Resistance Mechanisms

  • Mutations in tufA may confer resistance to antibiotics targeting the translational machinery

  • Altered expression levels may affect translation of resistance determinants

  • Potential role in persister cell formation within biofilms

  Supporting Evidence: Multiple drug-resistant (MDR) K. pneumoniae isolates have been found to form strong biofilms

• Surface Exposure and Host Interactions

  • Surface-exposed EF-Tu could interact with host components

  • May contribute to immune evasion within biofilms

  • Potential target for antibiofilm strategies

The following table summarizes the interconnections between EF-Tu, biofilm formation, and antimicrobial resistance in K. pneumoniae:

Understanding the relationship between EF-Tu, biofilm formation, and antibiotic resistance could lead to novel therapeutic strategies for combating K. pneumoniae infections, especially given the association between strong biofilm formation and multiple drug resistance observed in clinical isolates .

How can tufA sequence analysis contribute to molecular epidemiology of K. pneumoniae outbreaks?

The tufA gene provides a valuable molecular tool for epidemiological investigations of K. pneumoniae outbreaks through several analytical approaches:

• Sequence-Based Typing

  • Single nucleotide polymorphism (SNP) analysis within tufA

  • Identification of strain-specific sequence signatures

  • Integration with multi-locus sequence typing (MLST) schemes

  Analytical Advantage: tufA has been demonstrated to be an effective marker with monophyletic association, making it useful for species and strain identification

• Phylogenetic Analysis

  • Construction of phylogenetic trees to establish relationships between outbreak isolates

  • Determination of probable transmission chains

  • Identification of founder strains within healthcare facilities

  Methodology: Maximum likelihood or Bayesian inference methods using tufA sequence alignments

• Temporal Analysis

  • Molecular clock analysis to estimate time since most recent common ancestor

  • Tracking of evolutionary changes during prolonged outbreaks

  • Correlation with antimicrobial usage patterns

  Advantage: The relatively slow evolutionary rate of tufA makes it suitable for longer-term evolutionary analyses

• Geographical Mapping

  • Correlation of sequence types with geographical distribution

  • Tracking of inter-facility or international spread

  • Identification of regional variants with enhanced virulence or resistance

  Application: Global surveillance of high-risk clones

• Correlation with Clinical Outcomes

  • Association between specific tufA variants and disease severity

  • Identification of strains associated with leukopenia based on EF-Tu expression patterns

  • Prediction of outbreak potential based on molecular signatures

The integration of tufA sequence analysis with other molecular typing methods provides a comprehensive approach to outbreak investigation, particularly valuable for tracking the spread of multiple drug-resistant K. pneumoniae strains in healthcare settings. This molecular epidemiology approach can guide infection control measures and antimicrobial stewardship strategies.